CCPortal

浏览/检索结果: 共4条,第1-4条 帮助

限定条件        
已选(0)清除 条数/页:   排序方式:
Ecology of avian influenza viruses in migratory birds wintering within the Yangtze River wetlands 期刊论文
Science Bulletin, 2021
作者:  Wang D.;  Li M.;  Xiong C.;  Yan Y.;  Hu J.;  Hao M.;  Liang B.;  Chen J.;  Chen G.;  Yang G.;  Li Y.;  Zhang J.;  Gulyaeva M.;  Shestopalov A.;  Shi W.;  Bi Y.;  Liu H.;  Wang H.;  Liu D.;  Chen J.
收藏  |  浏览/下载:42/0  |  提交时间:2021/09/01
Avian influenza viruses  Migratory birds  Yangtze River wetlands  
Carbon monoxide powered fuel cell towards H2-onboard purification 期刊论文
Science Bulletin, 2021
作者:  Li Y.;  Wang X.;  Mei B.;  Wang Y.;  Luo Z.;  Luo E.;  Yang X.;  Shi Z.;  Liang L.;  Jin Z.;  Wu Z.;  Jiang Z.;  Liu C.;  Xing W.;  Ge J.
收藏  |  浏览/下载:54/0  |  提交时间:2021/09/01
CO electrooxidation  Hydrogen purification  Proton exchange membrane fuel cells  Rh based single atom catalyst  Turnover frequency  
SARS-CoV-2 nucleocapsid protein phase separates with G3BPs to disassemble stress granules and facilitate viral production 期刊论文
Science Bulletin, 2021, 卷号: 66, 期号: 12
作者:  Luo L.;  Li Z.;  Zhao T.;  Ju X.;  Ma P.;  Jin B.;  Zhou Y.;  He S.;  Huang J.;  Xu X.;  Zou Y.;  Li P.;  Liang A.;  Liu J.;  Chi T.;  Huang X.;  Ding Q.;  Jin Z.;  Huang C.;  Zhang Y.
收藏  |  浏览/下载:31/0  |  提交时间:2021/09/01
G3BP  Liquid-liquid phase separation  Nucleocapsid protein  SARS-CoV-2  Stress granules  Viral production  
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS) 期刊论文
Science Bulletin, 2021, 卷号: 66, 期号: 15
作者:  Jia W.;  Ma J.;  Miao H.;  Wang C.;  Wang X.;  Li Q.;  Lu W.;  Yang J.;  Zhang L.;  Yang J.;  Wang G.;  Zhang X.;  Zhang M.;  Sun L.;  Yu X.;  Du J.;  Shi B.;  Xiao C.;  Zhu D.;  Liu H.;  Zhong L.;  Xu C.;  Xu Q.;  Liang G.;  Zhang Y.;  Li G.;  Gu M.;  Liu J.;  Yuan G.;  Yan Z.;  Yan D.;  Ye S.;  Zhang F.;  Ning Z.;  Cao H.;  Pan D.;  Yao H.;  Lu X.;  Ji L.
收藏  |  浏览/下载:39/0  |  提交时间:2021/09/01
Chiglitazar  Glycemic control  Insulin resistance  PPAR pan-agonist  Type 2 diabetes